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The Warburg effect is ameliorated by culturing transformed cells in the presence of galactose 
instead of glucose as the primary carbon source. However, metabolic consequences that are in 
addition to sensitizing the cells to mitochondrial toxins may occur. As such, the screening of 
pharmaceutical agents against transformed cells while using galactose must be carefully evaluated. 
Pioglitazone is used in clinical applications to treat type-2 diabetes, but clearly has other off target 
effects. Human hepatocellular carcinoma cells (HepG2) were cultured in glucose or galactose-
containing medium to investigate the role of pioglitazone on cellular bioenergetics employing 
calorimetry and respirometry. Compared to cells cultured in 10 mM glucose, HepG2 cells cultured 
in the presence of 10 mM galactose showed decreased metabolic activity as measured by cellular 
heat flow. Interestingly, cellular heat flow increased after addition of pioglitazone for cells cultured 
in glucose, but not for cells cultured in galactose. Our calorimetric data indicate that a reduction 
in cellular capacity for glycolysis might be the mechanism responsible for the increase in 
sensitivity to pioglitazone, and likely mitochondrial toxins in general, for cells cultured in 
galactose. Furthermore, oxygen consumption rates were decreased after addition of pioglitazone 
to cells grown in glucose, but remained unchanged for cells grown in presence of galactose. Taken 
together, we demonstrate that pioglitazone induced a reduction in mitochondrial activity that was 
partially compensated via an increase in glycolysis in the presence of glucose.  
 





Thiazolidinediones (TZD) are effective insulin sensitizers used to treat type-2 diabetes, and 
these compounds have been shown to reduce the risk of conversion from impaired glucose 
tolerance to type-2 diabetes (Day 1999; DeFronzo et al. 2011). Most of the antidiabetic properties 
of TZDs are believed to be mediated through changes in gene expression patterns after binding to 
the nuclear peroxisome proliferator-activated receptor (PPAR)-γ (Cariou et al. 2012). However, 
mounting evidence indicates that at least part of TZD action is independent of PPAR-γ-mediated 
transactivation and transrepression of target genes (Feinstein et al. 2005). Pleiotropic mechanisms 
in addition to PPAR-γ binding appear to be crucial for the broad pharmacological profile of TZDs 
and potentially include several effects on mitochondria, including inhibition of the respiratory 
complex I (Brunmair et al. 2004), inhibition of the mitochondrial pyruvate carrier (Divakaruni et 
al. 2013), and binding to CISD1 (Colca et al. 2004; Geldenhuys et al. 2014; Paddock et al. 2007).  
First described nearly 60 years ago by Otto Warburg, highly proliferating cancer cells are 
often characterized by a shift in energy production from oxidative phosphorylation to glycolysis 
despite the presence of saturating concentrations of oxygen (‘aerobic glycolysis’) (Kim et al. 2006; 
Vander Heiden et al. 2009; Warburg 1956). In some cases, mitochondrial respiration rates can be 
rescued if glucose levels are low, and suppression in respiration by high glucose concentration is 
a phenomenon known as the Crabtree effect (Diaz-Ruiz et al. 2011; Ibsen 1961). For example, 
substitution of the primary energy substrate glucose by galactose increases mitochondrial activity 
in several models including adenocarcinoma (HeLa) and hepatocellular carcinoma (HepG2) cells, 
and sensitizes HepG2 cells to some mitochondrial toxins (Marroquin et al. 2007; Rossignol et al. 
2004). The reason for the increase in mitochondrial respiration in presence of galactose is still 
poorly understood. Glucose and galactose metabolism yields equivalent amounts of ATP and both 
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sugars are equal as energy sources, but the shift towards respiration might be due to flux limitations 
through the Leloir pathway (Frey 1996; Petry et al. 1998), since galactose enters glycolysis at a 
lower rate than glucose (Bustamante et al. 1977). However, in presence of galactose and glutamine, 
HeLa cells use glutamine to provide about 98% of the ATP used for cell growth (Reitzer et al. 
1979).  
A non-invasive method to directly measure the metabolic response of cells to drugs and 
changes in substrate availability is the simultaneous measurement of heat flow and oxygen flux 
(Gnaiger et al. 1990). This approach not only yields baseline estimates of energy flow, but can be 
used to evaluate the contribution of anaerobic pathways (e.g. glycolysis) to overall cellular energy 
homeostasis (Guan et al. 1999; Menze et al. 2010). We found a pronounced increase in chemically 
uncoupled cellular respiration, but a depression in heat dissipation for cells cultured in presence of 
galactose compared to glucose-cultured cells, indicating a shift in metabolic poise from glycolysis 
to respiration.  
We have investigated the effect of galactose and pioglitazone on bioenergetics and growth 
of HepG2 cells. Our results demonstrate that (1) galactose treatment shifts metabolic poise from 
glycolysis to oxidative phosphorylation, (2) pioglitazone treatment inhibits oxidative 
phosphorylation, (3) in presence of high glucose concentrations cells compensate for pioglitazone 
induced reductions in respiration via an increase in glycolysis and (4) a significant reduction in 
cell proliferation after addition of pioglitazone is observed in the presence of glucose, but absent 
if cells are dependent on galactose as a carbon source. Furthermore, increased metabolic activity 
induced by pioglitazone is abolished in galactose based medium. This study demonstrates that 
measuring cellular proliferation as an indicator of drug efficacy in the galactose-utilization model 
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Materials and methods 
All chemicals used for respirometry and solution preparations were of the highest grade and 
purchased from Sigma-Aldrich (St. Louis, MO), or Fisher Scientific (Fair Lawn, NJ). Human 
hepatocellular carcinoma cells (HepG2) were cultured in glucose free DMEM (Dulbecco's 
Modified Eagle Medium) supplemented with either 10 mM D-galactose or glucose following the 
protocol described in Stokich et al. 2014. Microcalorimetry was performed following the 
procedures detailed in Menze et al. 2010, and respirometry measurements were based on the 
methods described in Stokich et al. 2014. For detailed descriptions of the employed methods please 





Impact of Pioglitazone on Respiration of HepG2 Cells  
Significant reductions in oxygen flux by about 13% were observed after addition of 60 µM 
pioglitazone to cells respiring in cell culture medium containing 10 mM glucose (n = 6, p ≤ 0.05; 
Fig. 1A). A more pronounced inhibitory effect of pioglitazone on cellular respiration was observed 
if oxygen flux was stimulated via addition of FCCP, and routine respiration rates in control cells 
increased nearly 3-fold in presence of this potent chemical uncoupler. After the addition of 
pioglitazone, the uncoupled respiration rate was significantly inhibited by about 30% (n = 6, p ≤ 
0.05; Fig 1A). Moreover, pioglitazone acted as weak chemical uncoupler in intact cells, and proton 
leak respiration rates in the presence of the F0F1-ATPase inhibitor oligomycin (LEAKo) were 
significantly increased when pioglitazone was present (n = 6, p ≤ 0.05; Fig 1A). This significant 
mitochondrial uncoupling effect of pioglitazone was a common finding throughout this study, but 
we did not observe statistically significant increases in oxygen consumption rates of HepG2 
cultured in galactose for two weeks compared to glucose controls (n = 6, p > 0.05; Fig 1B). 
However, maximal uncoupled respiration (FCCP) was significant higher for cells cultured in 
galactose and the addition of pioglitazone did not reduce uncoupled respiration rates as observed 
for cells cultured in glucose. Furthermore, no increase in LEAKo respiration was observed in 
presence of pioglitazone (n = 6, Fig 1B).  
In order to elucidate the action(s) of pioglitazone on the oxidative phosphorylation system 
(OXPHOS) in more detail, HepG2 cells were permeabilized with digitonin and saturating levels 
of substrates were added to the sucrose based respiration medium. Two different titration 
protocols, promoting electron entry into the electron transport chain (ETS) via FADH2, or NADH 
and FADH2, were employed. In the first titration protocol, oxygen flux fueled by succinate 
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dehydrogenase (complex II) activity was measured in presence of the NADH:ubiquinone 
oxidoreductase (complex I) inhibitor rotenone and saturating levels of succinate. When using 
succinate as complex II substrate the addition of pioglitazone to permeabilized cells significantly 
stimulated oxygen flux compared to untreated control (n = 6, p ≤ 0.05; Fig 2A, B). For cells 
cultured in glucose medium, respiration rates after the addition of ADP did not differ between 
pioglitazone treated and control cells, demonstrating that pioglitazone does not cause significant 
reductions in the activities of succinate dehydrogenase or the mitochondrial phosphorylation 
system (Fig. 2A). As with intact cells a significant uncoupling effect of pioglitazone was observed 
after the addition of oligomycin (Fig. 2A, B). Interestingly, pioglitazone reduced OXPHOS rates 
in cells cultured in galactose medium (Fig. 2B).  
We next investigated the effect of pioglitazone on complex I activity followed by the 
concurrent presence of NADH and FADH2 generating substrates (Fig. 3A, B). A combination of 
malate, glutamate, and pyruvate was added to permeabilized cells to stimulate NADH production 
by mitochondrial dehydrogenases. In contrast to our results with succinate, no increase in oxygen 
flux was observed in presence of pioglitazone compared to untreated controls indicating an 
inhibition of NADH-poised respiration below an activity needed to establish a proton motive force 
(Δp) large enough to observe the uncoupling effect of pioglitazone (Fig. 3A). The same effect was 
observed for cells grown in galactose based medium (Fig. 3B). A severe inhibition in complex I 
activity was confirmed after addition of ADP. In presence of pioglitazone, ADP failed to stimulate 
oxygen flux, but similar to our results with succinate alone, respiration could be rescued by the 
addition of succinate. LEAKo respiration after addition of oligomycin was elevated by 63% in cells 
treated with pioglitazone if succinate was present and slightly higher in cells grown in galactose 
based medium (n = 6, p ≤ 0.05; Fig 3A, B).  
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Pioglitazone increased heat dissipation in presence of glucose but not galactose.  
Although the exact mechanism is unknown, some immortalized cells will shift energy 
production from glycolysis towards mitochondrial respiration in medium supplemented with 
galactose instead of glucose. In contrast to respirometry, calorimetry captures the overall metabolic 
activity including changes in glycolytic activity. HepG2 cells cultured in glucose medium or 
galactose medium were treated with 60 µM pioglitazone and heat dissipation was monitored every 
30 min for 2 h. During this period, heat dissipation dropped for galactose cultured cells, but not 
for cells measured in glucose medium (Table 1). However, after 30 min of exposure to 
pioglitazone, heat dissipation of HepG2 cells in glucose-containing medium was increased by 
about 15%, but no increase was observed for galactose-treated cells. Furthermore, overall heat 
output was about 17% lower for cells cultured in presence of galactose compared to cells in glucose 
medium (Table 1). Heat dissipation data demonstrated an overall reduction in metabolic activity 
and indicated that cells cultured in galactose-based medium might be characterized by an overall 
decrease in cellular proliferation. This was confirmed by following cellular growth, and the fold-
increase in cells per 24 h period decreased by about 40% if cells were grown in galactose based 
medium compared to glucose. A significant drop in proliferation rate was also observed after the 
addition of pioglitazone to cells grown in glucose-based medium. However, no additional decrease 
in proliferation was observed after the addition of pioglitazone to cells grown in galactose-based 







We have investigated the consequences of shifting metabolic poise of HepG2 cells from 
glycolysis to oxidative phosphorylation on pioglitazone-induced changes in metabolic activity. An 
increase in mitochondrial capacity was achieved by substituting glucose for galactose in the cell 
culture medium for two weeks. We found that pioglitazone reduced cellular respiration and 
increased glycolytic flux in cells cultured in presence of glucose, but not in cells cultured in 
galactose-based medium. Furthermore, pioglitazone severely inhibited complex I respiration in 
permeabilized cells, but the overall capacity for oxidative phosphorylation could be largely rescued 
by FADH2 production in presence of succinate. This capacity for compensation by complex II 
might be the reason for a less pronounced toxicity as might be expected based on the severely 
inhibition of complex I activity.  
Pioglitazone has been well known to alter mitochondrial bioenergetics. Acute effects of 
pioglitazone on primary hepatocytes and isolated mitochondria showed reductions in cellular and 
complex I fueled respiration rates (Brunmair et al. 2004; Sanz et al. 2011). Enzymatic assays on 
isolated mitochondrial complexes from mouse liver demonstrated decreases in complex I and III 
activity with increasing pioglitazone concentrations, and the drug was shown to disassemble 
complex I into 4 distinct subcomplexes (Garcia-Ruiz et al. 2013). We were interested in the effect 
of pioglitazone on highly proliferating HepG2 cells under in vivo conditions, since the relatively 
low toxicity of pioglitazone seemed difficult to explain based on the pronounced inhibition of 
complex I. We were especially interested to determine the effects of using the galactose model of 
cell culture on cellular energy flow in the presence of the known mitochondrial toxin pioglitazone. 
In absence of anaerobic pathways, the ratio of heat flux to oxygen flux (CR-ratio) will be in the 
range of the theoretical oxycaloric equivalent (-430 to -480 kJ mol O2) (Gnaiger et al. 1990). The 
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CR-ratio for HepG2 cells grown in glucose medium was elevated to -520 kJ/mol O2 indicating 
anaerobic contributions to energy production. In response to 60 µM pioglitazone, an increase in 
the CR-ratio to -720 kJ/mol O2 was observed, demonstrating an increase in glycolytic activity. 
Reductions in mitochondrial energy production due to inhibition of respiration by pioglitazone are 
apparently being counteracted by an increase in glycolytic flux. This increase in glycolytic flux 
was absence for cells cultured in galactose-based medium. In presence of galactose cells were less 
glycolytic poised with a CR-ration of -470 kJ/mol O2 and no increase in the CR-ratio was observed 
in response to pioglitazone.  
While galactose treatment of immortalized cells increases oxidative capacity of 
mitochondria, (Marroquin et al. 2007) and indeed rescues cells partially from the Warburg effect, 
sensitization to mitochondrial toxins may be obscured. We did not observe reduction in 
proliferation rates after pioglitazone addition to cells cultured in galactose. Only by combining 
proliferation studies with respirometry and calorimetry were we able to gain a further insight into 
the mechanism of action of pioglitazone. Therefore, caution is warranted in the interpretation of 
toxicity and efficacy studies of drug molecules in galactose-based culture studies in the absence of 
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Figure 1: Respiration rates of HepG2 cells cultured in glucose (A), or galactose (B) based medium 
for two weeks prior to respirometry. Oxygen flux is shown for control cells (black bars), and in 
presence of 60 µM pioglitazone (grey bars). Uncoupled respiration was induced by titrations with 
FCCP (FCCP), and leak respiration was recorded after inhibition of the F0F1-ATPase with 
oligomycin (Olig). *Indicates statistically significant differences after addition of pioglitazone. 
#Indicates statistically significant differences between cells cultured in glucose or galactose based 
medium (n = 6, ± SE).  
 
Figure 2: Respiration rates of HepG2 cells cultured in glucose (A), or galactose (B) based medium 
for two weeks prior to respirometry. Oxygen flux is shown for control cells (black bars), and in 
presence of 60 µM pioglitazone (grey bars). Respiration rates of cells permeabilized with digitonin 
(Dig) were recorded in presence of the Complex I inhibitor rotenone (Rot) and the substrate 
succinate (Succ). OXPHOS rates were measured after the addition of ADP (ADP), and leak 
respiration was recorded after inhibition of the F0F1-ATPase with oligomycin (Olig). *Indicate 
statistically significant differences after addition of pioglitazone (n = 6, ± SE).  
 
Figure 3: Respiration rates of HepG2 cells cultured in glucose (A) or galactose (B) based medium 
for two weeks prior to respirometry. Oxygen flux is shown for control cells (black bars), and in 
presence of 60 µM pioglitazone (grey bars). Respiration rates of cells permeabilized with digitonin 
(Dig) were recorded in presence NADH generating substrates (MGP) and OXPHOS rates were 
measured after the addition of ADP (ADP). Convergent electron entry into the ubiquinone pool 
was initiated by addition of succinate (Succ) and leak respiration was recorded after inhibition of 
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the F0F1-ATPase with oligomycin (Olig). *Indicate statistically significant differences after 
addition of pioglitazone. #Indicate statistically significant differences between cells cultured in 











1Cells were cultured and evaluated in galactose (Gal) or glucose (Glu) based medium, and response 
to 60 µM of pioglitazone (Pio), or DMSO (vehicle control, Vc) was recorded. The cells were 
cultured for a minimum of two weeks in presence of the respective sugar prior to calorimetry. 1all 
data are shown in µW. *statistically significant increase in heat dissipation after addition of 
pioglitazone. $statistically significant decrease in heat dissipation compared to glucose plus 
pioglitazone (n = 5-8, ± SE, P < 0.05).   
 
 





1Cells were cultured for two weeks in presence of galactose (Gal) or glucose (Glu) prior to the 
proliferation assays. Cells were plated in absence of drugs and 60 µM of pioglitazone (Pio), or 
DMSO (vehicle control, Vc) was added after 24 h. Cells were enumerated after an additional 24 h 
of incubation. *statistically significant decrease in cell proliferation after addition of pioglitazone. 
$statistically significant decrease in cell proliferation compared to cells cultured in glucose (n = 3, 
± SE P < 0.05).   
 
  
Condition1 30 min 60 min 90 min 120 min 
Glu (Vc) -22.49 ± 1.27 -22.97 ± 0.90 -22.46 ± 0.90 -22.24 ± 1.09 
Glu (Pio) -25.48* ± 0.99 -25.28*  ± 1.10 -24.75*  ± 0.97 -24.19*  ± 0.87 
Gal (Vc) -18.88 ± 1.00 -15.21 ± 0.62 -13.45 ± 0.59 -11.99 ± 0.64 
Gal (Pio) -18.64$ ± 0.99 -16.27$ ± 0.72 -14.91$ ± 0.60 -13.79$ ± 0.52 
Condition1 Fold-increase in cells 
Glu (Vc) 2.19 ± 0.15 
Glu (Pio) 1.77* ± 0.02 
Gal (Vc) 1.37$ ± 0.05 
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Supplemental Files - Material and Methods 
Chemicals 
All chemicals used for respirometry and solution preparations were of the highest grade 
and purchased from Sigma-Aldrich (St. Louis, MO), or Fisher Scientific (Fair Lawn, NJ). Water 
for solution preparation was purified with a Milli-Q Reagent Water System (Billerica, MA) to an 
electrical resistance of 18 mΩ.  
Cell culture 
Human hepatocellular carcinoma cells (HepG2) were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA) and grown in 75 cm2 cell culture flasks (Corning 
Incorporated, Corning, NY). Standard cell culture medium to maintain HepG2 cells was composed 
of Opti-MEM I reduced serum medium (ThermoFisher, Grand Island, NY) supplemented with 
5.5% fetal bovine serum (FBS) (Atlanta Biologicals Inc., Flowery Branch, GA), 100 units/ml 
penicillin, 100 µg/ml streptomycin, and 250 ng/ml amphotericin B (MP Biomedicals, Santa Anna, 
CA). Galactose treatment groups were cultured for a minimum of four weeks in glucose free 
DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10 mM D-galactose, 2 mM 
glutamine, 1 mM pyruvate (all from ThermoFisher, Grand Island, NY), plus 10 % dialyzed or 
complete FBS as indicated in the figure legends (Gal-DMEM). Gal-DMEM medium prepared with 
complete FBS contained >0.2 mM glucose (data not shown). For experiments directly comparing 
the impact of high glucose and galactose, cells were cultured in the above medium supplemented 
with 10 mM glucose instead of galactose (Glu-DMEM). The cells were maintained in a humidified 
atmosphere of 6.5% CO2 and 93.5% air at 37 °C and the culture medium was renewed every 3 - 4 
days. The cells were subcultured every seven days or before reaching 90% confluency. To 
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subculture, cells were dissociated using 0.25% trypsin and 1 mM EDTA in balanced salt solution 
(ThermoFisher, Grand Island, NY) and reseeded at 1.5 • 106 cells per 75 cm2 cell culture flasks. 
Microcalorimetry 
Heat dissipation of HepG2 cells was measured as described before (Menzeet al. 2010). 
Briefly, the LKB 2277 thermal activity monitor (Bromma, Sweden) was charged with a 4 mL 
sealed ampoule filled with 2.5 mL of HepG2 cells in suspension to measure heat dissipation. Cells 
were diluted in culture medium equilibrated with 10% CO2 and 90% air to yield 500,000 cells per 
2.5 mL of medium. The medium formulations (Gal-DMEM and Glu-DMEM) used to measure 
cellular heat dissipation were identical to the ones used for cell culture. The reference vessel 
contained 2.5 mL of water and all calorimetric measurements were performed at 37 °C. A 15 min 
period for thermal equilibration was allowed after the ampoule was lowered into the calorimeter, 
and the heat flow (µW) was recorded for 2 h. Pioglitazone stock solutions (6 mM) were prepared 
in dimethyl sulfoxide (DMSO). Heat dissipation of cells without pioglitazone was measured in 
presence of DMSO alone (vehicle control) and treated cells were exposed to a final concentration 
of 60 µM pioglitazone.  
Respirometry on HepG2 cells 
Respiration was measured at 37 °C using 1 × 106 cells per mL in each chamber of the 
Oxygraph-2K (OROBOROS Instruments, Innsbruck, Austria). Routine respiration of intact cells 
was measured in either Opti-MEM I reduced serum medium, DMEM supplemented with glucose, 
or DMEM supplemented with galactose. The media formulations in these experiments were 
identical to the media used to culture cells. In some experiments, cellular respiration was 
uncoupled by successive titrations of carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone 
(FCCP; 0.5 µM steps), and leak respiration was measured in the presence of oligomycin (2 µg/mL). 
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Oxygen consumption of permeabilized cells was measured in 2 mL of MiR05 (110 mM 
sucrose, 60 mM potassium lactobionate, 20 mM taurine, 10 mM KH2PO4, 3 mM MgCl2, 0.5 mM 
EGTA, 0.1% BSA, 20 mM HEPES-KOH, pH 7.1). In order to supply mitochondrial substrates, 
cells were permeabilized by the addition of digitonin dissolved in dimethyl sulfoxide (DMSO) at 
10 mg/mL (final concentration 10 µg × 10-6 cells). This digitonin concentration was found to be 
sufficient to permeabilize the plasma membrane of HepG2 cells with minimal impact on the 
integrity of the outer mitochondrial membrane as tested by addition of cytochrome c. Electron 
flow through complex I was stimulated by adding 2 mM malate, 10 mM glutamate, and 5 mM 
pyruvate. To engage the phosphorylation system, 1 mM ADP was added followed by the addition 
of 10 mM succinate to supply electrons to the ubiquinone pool via succinate dehydrogenase. Leak 
respiration in presence of ADP and ATP was measured after addition of oligomycin (2 µg/mL), 
and contribution of complex I to leak respiration was recorded after addition of rotenone (0.5 µM). 
Non-mitochondrial oxygen consumption was recorded after addition of 2.5 µM of antimycin A. 
DATLAB software (OROBOROS Instruments, Innsbruck, Austria) was used for data analysis and 
acquisition. 
Impact of pioglitazone on cell proliferation 
Approximately 500,000 cells were plated per well on 12-well plates, placed in a humidified 
atmosphere of 6.5% CO2 and 93.5% air at 37 °C, and grown in glucose or galactose containing 
medium. After 24 h cell counts were performed on untreated control cells. Samples for 
proliferation assays were exposed to pioglitazone concentrations of 0 or 60 µM and after an 
additional 24 h of culture time, treated and untreated cells were enumerated using a 
hemocytometer. Membrane integrity was assessed by diluting samples in a 1:1 ratio with trypan 
blue prior to cell counts and only trypan blue negative cells were used to calculate cellular 
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proliferation rates. Fold increase in cell numbers were expressed as numbers of cells recovered 
after 24 h of plating divided by cell numbers recovered after 48 h.  
Statistical analyses 
Data were analyzed with a one-way analysis of variance (ANOVA) on ranks followed by 
comparison of experimental groups with the appropriate control group (Holm-Sidak method), or 
2-way ANOVA followed by comparison of experimental groups with the appropriate control 
groups (Holm-Sidak method). SigmaPlot 12.5 (Systat Software Inc., San Jose, CA) was used for 
the analyses.  
 
 
